SHAWNEE, Kan., Jan. 31, 2011 /PRNewswire/ — Bayer Animal Health
announced this month at the North American Veterinary Conference,
the availability of its new products: Advantage® II for
cats and dogs, and K9 Advantix® II for dogs. These
products combine the adulticidal properties of the original
formulations of Advantage® Topical Solution and K9
Advantix®, with the insect growth regulator (IGR) pyriproxyfen,
which inhibits the development of flea eggs and kills flea larvae.
As a result, Advantage® II and K9 Advantix® II kill
all flea life stages and prevent fleas on a treated dog from
infesting the home. These products will be available in March
2011.
Pyriproxyfen, the added compound in Advantage® II and K9
Advantix® II, interferes with the hormone signaling of growing
insects so that fleas in immature stages are unable to mature.
The hormone pathway that pyriproxyfen targets is specific to
insects and does not affect mammals.
“Adding pyriproxyfen to the original formulations of
Advantage® Topical Solution and K9 Advantix® gives an added
layer of protection to our customers’ pets and their pets’
surroundings. It interrupts the flea life cycle at multiple
stages, and prevents reinfestation,” said Peter Ryan, Vice
President & Head, Companion Animal Business Unit, Bayer Animal
Health.
Advantage® II and K9 Advantix® II have adulticidal,
larvicidal and ovicidal properties, killing adult fleas and
preventing the emergence of new ones. Disrupting the flea
life cycle through different active ingredients and modes of action
is often referred to as integrated flea control (IFC).
Imidacloprid quickly paralyzes a flea’s mouthparts and kills
fleas through contact, so fleas don’t have to bite your pet to die.
By protecting pets from fleas, imidacloprid has been shown to
reduce the incidence of certain conditions including flea al
‘/>”/>
